Clarity Pharmaceuticals Announces Submission of Orphan Drug Designation Application for Cu-64 SARTATE™
Sydney, Australia 11 September 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has submitted an Orphan Drug Designation (ODD) request with the U.S. Food and Drug Administration (FDA) for 64Cu-SARTATE™, a diagnostic for the clinical management of neuroendocrine tumours (NETs). NETs are a…